VRDN Stock Overview
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
My Notes
NewNotes are coming soon
Viridian Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$35.80 |
52 Week High | US$39.00 |
52 Week Low | US$9.47 |
Beta | 1.01 |
1 Month Change | 30.37% |
3 Month Change | 88.62% |
1 Year Change | 79.09% |
3 Year Change | 186.00% |
5 Year Change | -56.61% |
Change since IPO | -80.28% |
Recent News & Updates
Recent updates
Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?
Jan 08Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market
Sep 09Viridian Therapeutics board compensation committee approves inducement grants
Sep 02An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued
Aug 22Viridian Therapeutics Q2 2022 Earnings Preview
Aug 12Viridian Therapeutics gets a new COO
Jun 23Viridian Therapeutics (VRDN) Investor Presentation - Slideshow
Jun 08Viridian Therapeutics reports Q1 results
May 06Miragen: Viridian Therapeutics Acquisition Offers Good Speculative Entry Opportunity
Dec 08Shareholder Returns
VRDN | US Biotechs | US Market | |
---|---|---|---|
7D | -2.0% | -0.8% | 0.9% |
1Y | 79.1% | 3.9% | -10.9% |
Return vs Industry: VRDN exceeded the US Biotechs industry which returned 4.3% over the past year.
Return vs Market: VRDN exceeded the US Market which returned -9.6% over the past year.
Price Volatility
VRDN volatility | |
---|---|
VRDN Average Weekly Movement | 9.0% |
Biotechs Industry Average Movement | 12.0% |
Market Average Movement | 6.7% |
10% most volatile stocks in US Market | 17.5% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: VRDN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: VRDN's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 50 | Jonathan Violin | https://www.viridiantherapeutics.com |
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.
Viridian Therapeutics, Inc. Fundamentals Summary
VRDN fundamental statistics | |
---|---|
Market Cap | US$1.44b |
Earnings (TTM) | -US$113.03m |
Revenue (TTM) | US$1.88m |
766.0x
P/S Ratio-12.7x
P/E RatioIs VRDN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VRDN income statement (TTM) | |
---|---|
Revenue | US$1.88m |
Cost of Revenue | US$83.97m |
Gross Profit | -US$82.09m |
Other Expenses | US$30.95m |
Earnings | -US$113.03m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -2.81 |
Gross Margin | -4,364.17% |
Net Profit Margin | -6,009.30% |
Debt/Equity Ratio | 1.1% |
How did VRDN perform over the long term?
See historical performance and comparison